Breast Neoplasms Clinical Trials in New Brunswick, New Jersey

7 studies are recruiting for breast neoplasms in New Brunswick, New Jersey right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer

   This is a Phase III trial where participants will be randomized to two treatment groups, which means participants will be assigned by equal chance to a treatment group. This trial will be double-blinded, which means neither the participants nor the trial doctors will know which of the two treatment…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Rutgers Cancer Institute of NJ (Rutgers, The State University of New Jersey), New Brunswick, New Jersey

   Locations

   202 in total

   Run by

   BioNTech SE

   See if you can join NCT07173751 on ClinicalTrials.gov

2. A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

   Researchers are looking for new ways to treat types of breast cancer that are both: * High-risk, which means the cancer may have a higher chance of getting worse or coming back after treatment * Early-stage, which means the cancer is in the breast or the lymph nodes around the breast The 2 types of…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Rutgers Cancer Institute of New Jersey ( Site 0076), New Brunswick, New Jersey

   Locations

   325 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT06966700 on ClinicalTrials.gov

3. Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer

   The purpose of this study is to evaluate the efficacy and safety of ctDNA-guided initiation of CDK4/6 inhibitor therapy using the Signatera™ Designed on Genome test (referred to as "Signatera Genome") in participants with intermediate-risk HR+/HER2- early-stage breast cancer. Based on ctDNA test re…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Rutgers, New Brunswick, New Jersey

   Locations

   49 in total

   Run by

   Natera, Inc.

   See if you can join NCT07214532 on ClinicalTrials.gov

4. A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

   Researchers are looking for other ways to treat breast cancer (BC) that is hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) and either unresectable locally advanced or metastatic. * HR positive (HR+) means the cancer cells have proteins that attach to estr…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Rutgers Cancer Institute of New Jersey ( Site 0033), New Brunswick, New Jersey

   Locations

   199 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT07060807 on ClinicalTrials.gov

5. Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)

   Researchers want to learn if patritumab deruxtecan (MK-1022) can treat certain breast cancers. The breast cancers being studied are HER2 positive unresectable locally advanced or metastatic (the cancer has spread to other parts of the body). The goals of this study are to learn: * About the safety …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Rutgers Cancer Institute of New Jersey ( Site 0052), New Brunswick, New Jersey

   Locations

   18 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT06686394 on ClinicalTrials.gov

6. I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

   The purpose of this study is to further advance the ability to practice personalized medicine by learning which new drug agents are most effective with which types of breast cancer tumors and by learning more about which early indicators of response (tumor analysis prior to surgery via magnetic res…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey

   Locations

   42 in total

   Run by

   QuantumLeap Healthcare Collaborative

   See if you can join NCT01042379 on ClinicalTrials.gov

7. DPYD Pharmacogenomics and Fluoropyrimidine (FP) Dose-Adjustment

   To prospectively evaluate the efficacy and safety of DPYD-guided dosing strategies in a real-world clinical setting, specifically by comparing the incidence of severe (Grade 3 and 4) fluoropyrimidine-related toxicities of heterozygous DPYD variant patients assigned to DPYD-guided reduced dosing ver…

   Stage

   Phase 4

   Ages

   18 and older

   Site

   Jack and Sheryl Morris Cancer Center, New Brunswick, New Jersey

   Locations

   12 in total

   Run by

   Rutgers, The State University of New Jersey

   See if you can join NCT07158164 on ClinicalTrials.gov